Mithra Pharmaceuticals releases 2016 Annual Report and invitation to its Ordinary General Shareholders’ Meeting

Liège, Belgium 18 April 2017 – Mithra Pharmaceuticals is pleased to announce the publication of its 2016 Annual Report and the invitation for its Ordinary General Shareholders’ meeting.

Annual Report

The Annual Report which outlines Mithra’s achievements in 2016 includes the following information:

  • Overview of Mithra’s R&D pipeline and letter to shareholders;
  • Highlights of Mithra’s strategy and outlook for 2017;
  • Corporate governance section;
  • Financial statements and notes.

François Fornieri, CEO Mithra Pharmaceuticals:  “During 2016 we made substantial progress on the key programs that we believe will deliver Mithra’s long-term international growth as a transformational leader in women’s health. We look forward to building on this progress in the year ahead as we move closer to commercializing Estelle® and to selecting a suitable partner to further develop Donesta®. We also anticipate filing for marketing approval for our vaginal contraceptive, Myring™, in both Europe and the US in 2017.”

Mithra releases its Annual Report in English and French. In case of interpretation differences, the English version will prevail. The report is available in English and French and can be downloaded on the website as a PDF file.

Ordinary General Shareholders’ meeting

The Ordinary General Shareholders’ meeting of Mithra Pharmaceuticals will be held on 18th May 2017 at 5:00 PM (CEST) in Liège (Belgium). Mithra Pharmaceuticals is pleased to invite its shareholders. The notice for the Ordinary General Shareholder’s meeting including a description of the formalities to participate in the Meeting is available on the website


Mithra Strengthens Position in the Belgian Contraception Market

  • Mithra builds on leading position in Belgian contraceptive market
  • Mithra achieves significant increase in 2016 sales
  • Market trend validates Mithra’s Estetrol-based programs

Liège, Belgium January 31, 2017 – Mithra Pharmaceuticals (Euronext Brussels: MITRA), a company focused on women’s health, today announces that it increased its market share in Belgium by 0.97% to 45.84% compared to 2015, placing it ahead of Bayer and Merck. The Company also achieved an increase in sales of 4.23%.

Mithra Announces 2017 Financial Calendar

Liège, Belgium 11 January 2017 – Mithra Pharmaceuticals (Euronext Brussels: MITRA), a company focused on women’s health, today announces its financial calendar for 2017.

  • 2 March 2017: Full Year Results 2016
  • 18 April 2017: Annual Report 2016
  • 18 May 2017: Annual General Meeting 2017
  • 12 September 2017: Half Year Results 2017

This schedule is indicative and subject to change.

The calendar is also available on Mithra’s Investor website:

Openbaarmaking van een transparantiekennisgeving ontvangen door Mithra Pharmaceuticals NV

Luik, België 09 januari 2017 – Gereglementeerde informatie – Overeenkomstig artikel 14 van de wet van 2 mei 2007 op de openbaarmaking van belangrijke deelnemingen, maakt Mithra Pharmaceuticals NV bekend dat zij verschillende transparantieverklaringen heeft ontvangen.

Mithra Pharmaceuticals NV ontving een op 29 december 2016 gedateerde transparantiekennisgeving, waaruit blijkt dat Bart Versluys (Versluys Invest BVBA, Versluys Bouwgroep BVBA), als gevolg van netto-aankopen van aandelen, nu 3,28% van de stemrechten van Mithra Pharmaceuticals NV (totale aantal stemrechten : 31.129.756) bezit en dus de deelnemingsdrempel van 3% overschreden heeft.

Appointment of Christophe Maréchal as Chief Financial Officer

Liège, Belgium, 6 January 2017 – Mithra Pharmaceuticals (Euronext Brussels: MITRA), a company focused on women’s health, today announces the appointment of Christophe Maréchal as Chief Financial Officer (CFO) with effect from 23 February 2017.

Mithra Will Propose Christiane Malcorps as new Independent Board Member / Phase III Clinical Study for Estelle® in us Launched With First Randomized Patient

Liège, Belgium, 23rd September 2016 –Today, Mithra announces that Christiane Malcorps will be proposed as a new member of Mithra’s Board of Directors (Mithra SA) during the next Shareholders meeting. She also is appointed as member of the Board of Mithra’s CDMO (Development and production center).

Liège, Belgium 23rd September 2016 – Mithra announces today that the first patient has been randomized in the American Phase III clinical trials for its Estetrol-based product candidate Estelle® (E4/DRSP). The enrollment of this first patient marks the official launch of the Estelle® (E4/DRSP) Phase III clinical trial in United States. With this, the Phase III is fully in line with the timing and objectives announced in the Prospectus.

Download the press release

Mithra Pharmaceuticals Announces its First Half 2016 Financial Results and Operational Progress

Liège, Belgium 1 September 2016, 07h30 – Mithra Pharmaceuticals, a leader in Women’s Health market, today announced its consolidated financial results for the six-month period ending 30 June 2016 prepared in accordance with article 13 of the Royal Decree of 14 November 2007. The full interim financial report (regulated information) is available on our website in the Investors section.

Read the press releaseDownload the report

Marc Coucke Appointed Chairman of Mithra’s Board of Directors

  • Mithra Pharmaceuticals announced today the appointment of Marc Coucke as chairman of the Board of Directors.
  • Other changes also occured in the Board of Directors of Mithra Pharmaceuticals.
  • Koen Hoffman, CEO of Value Square and former CEO of KBC Securities, was appointed independent director and will become chairman of the audit committee of Mithra.
  • Freya Loncin, General Counsel Alychlo, was appointed new non-executive director.
  • Professor Jean-Michel Foidart, co-founder of Mithra and current co-chairman of the Scientific Committee of Mithra Pharmaceuticals, was appointed non-executive director.

Liège, Belgium, 26 August 2016 – During the last board meeting, the Board of Directors of Mithra unanimously appointed Marc Coucke as Chairman.

Read the press release